CDK4/6 Inhibitors for HR+ Breast Cancer; Emergence of Ribociclib

Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.

Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.

The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.

Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.

The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.

Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.